ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Mayo Clinic at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Mayo Clinic takes part in 20 sessions at ESMO 2026 in Madrid. Its program covers treatment outcomes and care across several cancers, including neuroendocrine tumours and lung cancer. Specific topics include radioligand therapy for neuroendocrine tumours and real-world comparisons of treatments for cancers that have spread to bone.
| Organization | ESMO 2026 Attendance |
|---|---|
Mayo Clinic Rochester, MN | |
Nonprofit academic medical centre in Rochester, Minnesota, with an NCI-designated comprehensive cancer centre. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Genomic testing and prevalence of kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation in advanced non-small cell lung cancer (aNSCLC) in the U.S. Lung & thoracic cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Chair Fri Oct 23 13:30–15:00 Rapid oral: CNS tumours Sarcoma, CNS, head & neck and rare cancers Abstract Fri Oct 23 13:45–13:57 Invited Discussant 695RO, 696RO and 697RO Sarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Abstract Fri Oct 23 16:25–16:30 Chair Sat Oct 24 10:15–11:45 Theranostics: A magic bullet story from theory to clinics Sarcoma, CNS, head & neck and rare cancers Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Real world survival outcomes associated with aspirin (ASA) use in anal squamous cell carcinoma (ASCC) treated with chemoradiation: A propensity score matched analysis from global federated health research network Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Chair Sun Oct 25 14:45–16:15 Radioligand therapy: A game-changer in the treatment sequence of advanced neuroendocrine tumors Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 15:45–16:05 Looking ahead: Next frontiers of radioligands in neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Comparative survival of stage IV combined small-cell lung cancer (SCLC), pure SCLC, and non-small-cell lung cancer subtypes in the immunotherapy era: A propensity score-matched analysis of the National Cancer Database Lung & thoracic cancersSarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Predicting immunotherapy and platinum therapy response in extrapulmonary neuroendocrine carcinomas by tumor microenvironment transcriptomics Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 Real-world management of extrapulmonary neuroendocrine carcinoma (epNEC) from the perspective of healthcare providers in the VOICE study Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Satellite Mon Oct 26 18:45–19:15 Satellite Mon Oct 26 19:15–19:25 Satellite Mon Oct 26 19:25–19:40 |
Find decision makers at Mayo Clinic
Tell us what you sell and we’ll find the people at Mayo Clinic most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction